Drugs or Vaccines in Phase 2 Clinical Trials in Patients with COVID-19
This is as of June 7, 2020.
For the interest of understanding currently ongoing clinical trials for a list of representative drugs in patients with COVID-19, the following provides a list of drugs which are currently being tested in phase II clinical trials. In other words, this is a list of representative drugs, biologicals, plasma, or others being tested in human phase II clinical trials currently recruiting patients with COVID-19.
The list is based on 221 clinical trials involving COVID-19 conducted around the world.
NOTE: Each numbered item under each country represents listed drug(s) tested in a Phase II clinical trial study registered at the database of privately and publicly funded human clinical trials/studies on a global basis (ClinicalTrials.gov). Placebo (oral tablet or saline injection) or standard care as a control is not listed.
The names of countries are not in alphabetical order.
United States
- Sarilumab
- Biological: anti-SARS-CoV-2 convalescent plasma
- Dociparastat sodium
- Biological: Convalescent Plasma; Biological: Lactated ringer’s solution or sterile saline
- Etoposide
- MSTT1041A/MSTT1041A-matched Placebo; UTTR1147A/UTTR1147A-matched Placebo
- Baricitinib and Hydroxychloroquine
- SNDX-6352
- Peginterferon Lambda-1a
- : PUL-042 Inhalation Solution
- PUL-042 Inhalation Solution
- Leronlimab (700mg)
- Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma) with
Control (albumin 5%) - Favipiravir + Standard of Care
- Biological: Convalescent Plasma (anti-SARS-CoV-2 plasma) with
Non-convalescent Plasma (control plasma) - Hydroxychloroquine
Hydroxychloroquine and Azithromycin
Hydroxychloroquine and Ivermectin
Camostat Mesilate - Biological: MultiStem
- Tocilizumab
- BLD-2660
- Saline oral/nasal rinse
0.5% Povidone/Iodine oral/nasal rinse
0.12% Chlorhexidine oral/nasal rinse - ATYR1923 1 mg/kg
ATYR1923 3 mg/kg - Tociliuzumab
- Biological: Biological: mRNA-1273: 50 mcg
Biological: Biological: mRNA-1273: 100 mcg - BMS-986253
- High-Titer Anti-SARS-CoV-2 (COVID 19) Convalescent Plasma
- N-acetylcysteine and Peripheral Blood
- Convalescent Plasma
- Hydroxychloroquine and Radiation: Radiation therapy
- Hydroxychloroquine
Indomethacin
Zithromax Oral Product - Selinexor
- Leronlimab (700mg)
- Biological: CYNK-001
- Canakinumab Injection 600mg and Canakinumab Injection 300mg
- Mavrilimumab
- Peginterferon lambda alfa-1a subcutaneous injection
Hydroxychloroquine- Drug: MethylPREDNISolone 80 Mg/mL Injectable Suspension (Puerto Rico)
- Veru-111
- Estradiol patch
- Biological: Convalescent Plasma
- Nitric Oxide
- Hydroxychloroquine and Azithromycin
- Prazosin
- Hydroxychloroquine (HCQ) and Calcium citrate
- Convalescent Plasma
- Hydroxychloroquine Sulfate 400 mg twice a day
Hydroxychloroquine Sulfate 600 mg twice a day
Hydroxychloroquine Sulfate 600 mg once a day
Placebo oral tablet - Tocilizumab
- Clazakizumab 25 mg
Clazakizumab 12.5 mg - Povidone-Iodine Nasal Spray and Gargle
- Combination Product: Hydroxychloroquine Sulfate + Azithromycin
Drug: Hydroxychloroquine Sulfate - LY3127804
- Gimsilumab
- Nitric Oxide Gas
Other: Inhaled Supplemental Oxygen - Atovaquone/Azithromycin
- Fluvoxamine
- Ibrutinib
- GLS-1200
- Hydroxychloroquine or/both
Azithromycin to treat severe SARS-CoV-2 infection - Sirukumab
- Naltrexone
Ketamine - Aviptadil by intravenous infusion + standard of care
- Vazegepant (BHV-3500)
- Dipyridamole 100 Milligram(mg)
- TJ003234
- Convalescent plasma
- Ascorbic Acid
Hydroxychloroquine Sulfate
Azithromycin
Folic Acid - Hydroxychloroquine (Columbia University)
- Heparin
- Losartan
Hydroxychloroquine (University of Utah)- CM4620-Injectable Emulsion
- Hydroxychloroquine Sulfate
Ascorbic Acid - L-ascorbic acid
- lopinavir/ritonavir
Hydroxychloroquine Sulfate
Losartan - Umbilical Cord Mesenchymal Stem Cells
- Chloroquine (Columbia University)
- Low Dose Radiation Therapy
South Korea
- Clevudine and Hydroxychloroquine
United Kingdom
- TD-0903
- Interferon beta 1a
- Biological: Human umbilical cord derived CD362 enriched MSCs
Biological: Placebo (Plasma-Lyte 148) - Biological: Human umbilical cord derived CD362 enriched MSCs
- Interleukin-7
- nebulised recombinant tissue-Plasminogen Activator (rt-PA)
- Lopinavir-Ritonavir
Corticosteroid
Hydroxychloroquine
Azithromycin
Biological: Convalescent plasma
Tocilizumab
China
- Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Biological: Low dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Biological: Medium dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 28-day schedule
Biological: High dosage Inactivated SARS-CoV-2 Vaccine on a 0- and 14-day schedule
Biological: Placebo on a 0- and 28-day schedule
Biological: Placebo on a 0- and 14-day schedule - Biological: NK cells,IL15-NK cells,NKG2D CAR-NK cells,ACE2 CAR-NK cells,NKG2D-ACE2 CAR-NK cells
- Fingolimod 0.5 mg
- Biological: MSCs
Biological: Saline containing 1% Human serum albumin(solution of MSC) - Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the emergency vaccination schedule
Biological: Two doses of placebo at the emergency vaccination schedule
Biological: Two doses of medium dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Biological: Two doses of high dosage inactivated SARS-CoV-2 vaccine at the routine vaccination schedule
Biological: Two doses of placebo at the routine vaccination schedule - UC-MSCs
- Biological: allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC)
- Injection and infusion of LV-SMENP-DC vaccine and antigen-specific CTLs
- N-acetylcysteine+ Fuzheng Huayu Tablet
N-acetylcysteine+Placebo - Interferon Beta-1B and Hydroxychloroquine (Hong Kong)
- Biological: CAStem
- VC
- Meplazumab for Injection
Spain
- Tocilizumab
- Biological: Pembrolizumab (MK-3475)
- Hidroxicloroquine, Lopinavir/ritonavir, Imatinib tablets, and Baricitinib Oral Tablet
- Siltuximab and Methylprednisolone
- Biological: Mesenchymal Stromal Cells
- Ruxolitinib plus simvastatin
- Tocilizumab
Hydroxychloroquine
Azithromycin - Sarilumab
- Defibrotide 25 mg/kg 24 hours continuous infusion for 15 days
- Ivermectin
- Biological: Hyperimmune plasma
- Allogeneic and expanded adipose tissue-derived mesenchymal stem cells
- XCEL-UMC-BETA
France
- ABX464
- LEAF-4L6715 and LEAF-4L7520
- Transfusion of COVID-19 convalescent plasma
- Prednisone
- Eculizumab
- Hydroxychloroquine
Azithromycin - Chloroquine analog (GNS651)
Nivolumab
Tocilizumab - IgIV
- Combination Product: Hyperbaric oxygen treatment (HBOT)
- Biological: Umbilical cord Wharton’s jelly-derived human
- Hydroxychloroquine + placebo
hydroxychloroquine + azithromycin
Canada
- Peginterferon Lambda-1A
- NORS (Nitric Oxide Releasing Solution)
- Lopinavir/ritonavir
Hydroxychloroquine sulfate
Baricitinib (janus kinase inhibitor) - Lopinavir/ritonavir
Hydroxychloroquine
Remdesivir - Icosapent ethyl
Germany
- Ruxolitinib
- Hydroxychloroquine
- Hyperbaric oxygen
- Biological: BNT162a1
Biological: BNT162b1
Biological: BNT162b2
Biological: BNT162c2
Mexico
- Biological: convalescent plasma
- Biological: Convalescent Plasma of patients with COVID-19 and Other: placebo (hartmann plus albumine)
- Biological: Plasma
- Tocilizumab
- Biological: Infusion IV of Mesenchymal Stem cells
- Convalescent plasma
- Ruxolitinib Oral Tablet
- Pyridostigmine Bromide
- Colchicine
Israel
- ArtemiC
Italy
- Tocilizumab Injection
- Colchicine 1 MG Oral Tablet
- Biological: Emapalumab
Biological: Anakinra - Radiation: Single fraction whole lung radiotherapy
- Hydroxychloroquine
- Other: plasma hyperimmune
- Biological: COVID-19 Convalescent Plasma
- Oxygen-ozone therapy, probiotic supplementation and Standard of care
Dietary Supplement: SivoMixx (200 billion)
Azithromycin
hydroxychloroquine - Colchicine
- Convalescent plasma
- Bevacizumab Injection
- Escin
Netherlands
- Best supportive Care (BSC) + IFX-1 and Best supportive care only
- Biological: Convalescent plasma
Greece
- Procedure: Convalescent Plasma
- T3 solution for injection
- Biological: Mesenchymal cells
- Clarithromycin
- Anakinra
Tocilizumab - Anakinra
trimethoprim/sulfamethoxazole - Telerehabilitation
Denmark
- DFV890
- Dietary Supplement: Nicotinamide riboside
Dietary Supplement: Placebo - RoActemra iv
RoActemra sc
Kevzara sc - Camostat Mesilate
Austria
- Azithromycin 500 milligram (mg) oral Tablet
- RhACE2 APN01
- Chloroquine or Hydroxychloroquine
Lopinavir/Ritonavir
Bangladesh
- Biological: Convalescent plasma
- Favipiravir
Chile
- Biological: COVID-19 convalescent plasma
Saudi Arabia
- convalescent plasma from recovered COVID 19 donor
- Hydroxychloroquine
- Dietary Supplement: Nigella sativa
Switzerland
- Tocilizumab (TCZ)
Sweden
- Biological: SARS-CoV-2 convalescent plasma
Argentina
- Telmisartan arm will receive 80 mg Telmisartan twice daily plus standard care.
- IVERMECTIN (IVER P®) arm will receive IVM 600 µg / kg once daily
Ecuador
- Dietary Supplement: Viusid and Asbrip
Australia
- Biological: SARS-CoV-2 rS
Other: Matrix-M Adjuvant
Other: NSS Saline Placebo
Russian Federation
- Biological: COVID-19 convalescent hyperimmune plasma
Biological: Non-convalescent fresh frozen plasma (Standard plasma) - Melphalan
- RPH-104 80 mg
Olokizumab 64 mg - Colchicine
Ruxolitinib 5 MG
Secukinumab 150 MG/ML Subcutaneous Solution [COSENTYX] - Azoximer bromide
Vietnam
- Chloroquine phosphate
Iran
- Colchicine Tablets
- Deferoxamine
- Oral administration of Colchicine plus Herbal Phenolic Monoterpene Fractions
- Levamisole Pill + Budesonide+Formoterol inhaler
Lopinavir/Ritonavir + hydoxychloroquine - Oral 25-Hydroxyvitamin D3
- Low Dose Radiotherapy
Pakistan
- Hydroxychloroquine Sulfate 200 MG
Poland
- Amiodarone
Verapamil
Bosnia and Herzegovina
- metenkefalin + tridecactide
Brazil
- Chloroquine Diphosphate
- Methylprednisolone Sodium Succinate
Norway
- Hydroxychloroquine
Remdesivir
Turkey
- MSC Treatment
It should be noted that this list is under development and it is not intended to be exhaustive.
US Food and Drug Administration (FDA)
- FDA Guidance on Conduct of Clinical-Trial During-COVID-19
- FDA List of COVID-19-Related FDA Guidance Documents (As of June 7, 2020)
Last Updated: 2020-06-07
Comments are closed.